In liver cancer, prostate cancer, and renal cell carcinoma, high plasma levels of TGF-β are also associated with increased tumor angiogenesis and poor prognosis in these cancers [60, 61]. This evidence concerns the gene TGFB1 and Familial prostate cancer.